Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
14:56:58 EDT Mon 24 Mar 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

T:MDNA - MEDICENNA THERAPEUTICS CORP. J - https://www.medicenna.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MDNA - T  1.10.99·1.004.81.0039.5371091.02  1.06  0.982.98  0.8914:36:08Feb 2515 min RT 2¢
TSX - T1.10.99·1.004.80.99-0.01-1.026.024461.02  1.03  0.982.98  0.8914:16:3415 min
NEO ATS - U 1.001.6261.00  1.00  1.0014:36:0815 min
Omega - O 1.001.5150.98  1.00  0.9814:36:0815 min
Pure - P 1.002.93111.02  1.04  1.0012:37:0715 min
Chi-X - X 1.01+0.011.03.43151.05  1.06  1.0112:37:0615 min
CX2 - H 1.002.93171.03  1.03  1.0014:36:0815 min
CXD - D 0.995-0.005-0.50.5040.995  0.995  0.99514:23:4315 min
TriAct - M 1.000.705    Sep 11/2015 min

Recent Trades - Last 10 of 109
Time ETExPriceChangeVolumeBuyerSellerMarkers
14:36:08U1.00 10089 Raymond James2 RBCK
14:36:08U1.00 50089 Raymond James2 RBCK
14:36:08O1.00 60089 Raymond James2 RBCK
14:36:08H1.00 1,00089 Raymond James1 AnonymousK
14:36:08O1.00 20089 Raymond James2 RBCK
14:36:08U1.00 20089 Raymond James2 RBCK
14:36:08H1.00 20089 Raymond James2 RBCK
14:36:08H1.00 10089 Raymond James1 AnonymousK
14:36:08O1.00 10089 Raymond James13 InstinetK
14:36:08U1.00 10089 Raymond James2 RBCK

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolPriceTypeHeadline
2025-02-25 15:46C:MDNA1.13News ReleaseMedicenna talks MDNA11 Ability-1 study data
2025-02-13 10:28C:MDNA1.27News ReleaseMedicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones
2025-02-12 21:03C:MDNA1.27SEDAR Interim MD & ASEDAR Interim MD & A
2025-02-05 07:00C:MDNA1.26News ReleaseMedicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025
2024-12-13 08:30C:MDNA1.81News ReleaseMedicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)
2024-12-05 07:35C:MDNA1.66News ReleaseMedicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA(TM) (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study
2024-11-27 07:00C:MDNA1.77News ReleaseUpdated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference
2024-11-25 07:30C:MDNA1.57News ReleaseMedicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)
2024-11-15 07:30C:MDNA1.70News ReleaseMedicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update
2024-11-14 19:42C:MDNA1.70SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2024-11-14 19:42C:MDNA1.70SEDAR Interim MD & ASEDAR Interim MD & A
2024-11-11 11:31C:MDNA2.22News ReleaseMedicenna talks MDNA11 Ability-1 study results
2024-11-08 10:00C:MDNA2.47News ReleaseMedicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
2024-10-15 07:00C:MDNA2.23News ReleaseOTC Markets Group Welcomes Medicenna Therapeutics Corp. to OTCQX
2024-09-26 18:27C:MDNA1.88News ReleaseMedicenna Therapeutics holders approve AGM resolutions
2024-09-09 16:40C:MDNA2.22News ReleaseMedicenna presents preclinical results in France
2024-08-27 07:00C:MDNA2.16News ReleaseMedicenna Announces Upcoming Presentations at The Promise of Interleukin-2 Therapy Conference
2024-08-15 15:46C:MDNA2.13News ReleaseMedicenna Therapeutics appoints Lalji to board
2024-08-01 07:00C:MDNA2.13News ReleaseMedicenna Reports First Quarter Fiscal 2025 Financial Results and Announces First Complete Responder with MDNA11 Monotherapy
2024-07-31 21:27C:MDNA2.13SEDAR Interim Financial StatementsSEDAR Interim Financial Statements